DS-8201 + Nivolumab: combination therapy for HER2-expressing tumors: In a phase 1b study designated DS8201-A-U105 (NCT03523572), researchers explored the potential of combining DS-8201 with Nivolumab for patients with HER2-expressing advanced/metastatic tumors, with a focus on two cohorts dedicated to BC. This evidence concerns the gene ERBB2 and breast cancer.